首页> 外文期刊>癌症生物学与医学(英文版 ) >Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
【24h】

Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer

机译:HER2阳性乳腺癌特异性分子成像的临床前和临床应用

获取原文
获取原文并翻译 | 示例
           

摘要

Precision medicine and personalized therapy are receiving increased attention, and molecular-subtype classification has become crucial in planning therapeutic schedules in clinical practice for patients with breast cancer. Human epidermal growth factor receptor 2 (HER2) is associated with high-grade breast tumors, high rates of lymph-node involvement, high risk of recurrence, and high resistance to general chemotherapy. Analysis of HER2 expression is highly important for doctors to identify patients who can benefit from trastuzumab therapy and monitor the response and efficacy of treatment. In recent years, significant efforts have been devoted to achieving specific and noninvasive HER2-positive breast cancer imaging in vivo. In this work, we reviewed existing literature on HER2 imaging in the past decade and summarized the studies from different points of view, such as imaging modalities and HER2-specific probes. We aimed to improve the understanding on the translational process in molecular imaging for HER2 breast cancer.
机译:精密医学和个性化治疗受到越来越多的关注,并且分子亚型分类对于规划乳腺癌患者的临床实践治疗方案至关重要。人表皮生长因子受体2(HER2)与高度乳腺肿瘤,高淋巴结受累率,高复发风险以及对普通化疗的高耐药性有关。 HER2表达的分析对于医生确定可从曲妥珠单抗治疗中受益并监测治疗反应和疗效的患者非常重要。近年来,已经做出了巨大的努力来实现体内特异性的和非侵入性的HER2阳性乳腺癌成像。在这项工作中,我们回顾了过去十年中有关HER2成像的文献,并从不同的角度总结了研究,例如成像方式和HER2特异性探针。我们旨在增进对HER2乳腺癌分子成像中翻译过程的理解。

著录项

  • 来源
    《癌症生物学与医学(英文版 )》 |2017年第3期|271-280|共10页
  • 作者单位

    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy, Tianjin;

    Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;

    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy, Tianjin;

    Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;

    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy, Tianjin;

    Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;

    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy, Tianjin;

    Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;

    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy, Tianjin;

    Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;

    Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy, Tianjin;

    Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号